From WVI: "...,In this study, we investigated the receptor usage of the SL-CoV S by combining a human immunodeficiency virus-based pseudovirus system with cell l

From WVI: "...,In this study, we investigated the receptor usage of the SL-CoV S by combining a human immunodeficiency virus-based pseudovirus system with cell lines expressing the ACE2 molecules of human, civet, or horseshoe bat... Several important observations were made from this study... Third, the chimeric S covering the previously defined receptor-binding domain *gained its ability to enter cells via human ACE2*, albeit with different efficiencies for different constructs. Fourth, a minimal insert region (amino acids 310 to 518) *was found to be sufficient to convert the SL-CoV S from non-ACE2 binding to human ACE2 binding*..." This is *published research*. Specifically observations 3 and 4 https://jvi.asm.org/content/jvi/82/4/1899.full.pdf https://jvi.asm.org/content/jvi/82/4/1899.full.pdf